Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
The evidence is not clear: Rheumatic diseases, drugs, and COVID-19
Key clinical point: For rheumatologists, quality evidence on COVID-19 is in short supply.
Major finding: Over 1,700 articles encompassing COVID-19, rheumatic diseases, and drugs for such diseases have been published.
Study details: PubMed search from Jan. 1, 2019, to June 24, 2020.
Disclosures: No sponsor was declared, and no conflicts of interest were reported.
Citation:
Kroon FPB et al. Ann Rheum Dis. 2020 Aug 12. doi: 10.1136/annrheumdis-2020-218483.